Annexon, Inc.

NASDAQ•ANNX

CEO: Mr. Douglas Love Esq., J.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2020-07-24

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

連絡先情報

1400 Sierra Point Parkway, Building C Suite 200, Brisbane, CA, 94005, United States

650-822-5500

www.annexonbio.com

時価総額

$649.40M

PER (TTM)

-3.9

17.8

配当利回り

52週高値

$7.18

52週安値

$1.29

52週レンジ

70%

順位57Top 83.3%

2.4

F-Score

改良版 Piotroski 分析

8年ファンダメンタル

弱い • 2.4 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2018-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.37+48.00%

直近4四半期の推移

フリーCF

-$52.35M+63.48%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

R&D Expenses Surge 87% Nine-month R&D expenses reached $142.0M, increasing $65.9M (87%) driven by clinical trial advancement and technology transfer.

Liquid Assets $188.7M Available cash and short-term investments totaled $188.7M as of September 30, 2025, funding operations into Q1 2027.

Net Loss Widens Significantly Nine-month net loss increased 77% to $158.4M in 2025, primarily due to increased operating expenses supporting pipeline progression.

ATM Equity Proceeds Raised Sold $13.5M net proceeds from common stock via 2024 ATM program during the nine months ended September 30, 2025.

リスク要因

Substantial Additional Financing Needed Future viability beyond Q1 2027 depends on obtaining necessary capital; failure to secure funding could halt development programs.

Clinical Data Uncertainty High Success hinges on positive Phase 3 results for vonaprument (GA) and tanruprubart (GBS); regulatory acceptance is not assured.

Reliance on Third-Party Manufacturing Complete dependence on external partners for clinical and commercial supply introduces risks regarding quality control and delivery timelines.

Intellectual Property Enforcement Costs Commercial success relies on enforcing IP rights, facing risks from costly litigation and potential patent invalidation challenges.

見通し

GBS MAA Submission Planned Anticipate Marketing Authorization Application (MAA) submission for tanruprubart in GBS to European regulators in January 2026.

GA Phase 3 Data Expected Topline data for the global Phase 3 ARCHER II trial for vonaprument in GA is planned for reporting in the second half of 2026.

Continue High Operating Expenses Expect R&D expenses to increase further while advancing late-stage trials and investing in capabilities to prepare for commercialization.

ANX1502 POC Update 2026 Evaluating ANX1502 in CAD patients; plan to provide profile update upon completion of the ongoing Phase 1 study in 2026.

同業比較

売上高 (TTM)

EDIT

$46.38M

-24.9%

ALEC

$21.05M

-79.1%

BLRX

$12.74M

-42.1%

粗利益率 (最新四半期)

KRRO

100.0%

+0.0pp

LYEL

100.0%

+0.0pp

EDIT

100.0%

+2621.3pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ANNX	$649.40M	-3.9	-92.3%	11.8%
REPL	$581.31M	-2.1	-102.7%	23.6%
DBVT	$528.19M	-3.3	-295.2%	14.5%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月11日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし